2cureX AB publishes interim report for January – September 2018

2cureX AB (”2cureX”) hereby publishes the interim report for the first nine months of 2018. The interim report is available via attached file and on the company’s website (www.2curex.com). Below follows a short summary of the interim report.

The first nine months (2018-01-01 until 2018-09-30) – the group

• Net turnover for the period was 0 KSEK (0 KSEK).
• The result after tax was -6,759 KSEK (-3,078 KSEK).
• The result per share* was -0.65 SEK (-0.38 SEK).
• The solidity** was 51 % (50 %).
• The cash and bank were 23,848 KSEK (5,000 KSEK).

Third quarter (2018-07-01 till 2018-09-30) – the group

• Net turnover for the period was 0 KSEK (0 KSEK).
• The result after tax was -711 KSEK (-301 KSEK).
• The result per share* was -0.07 SEK (-0.04 SEK).

*Result per share: The result of the period divided by the average number of shares. Average number of shares for the third quarter 2018:
10 350 000 shares. Total number of shares in 2cureX AB on September 30th, 2018: 10 350 000 shares.

**Solidity: Equity divided by total capital.

Significant events during the third quarter 2018

• 2cureX receives an approval from the European Patent Office (EPO) concerning the patent “Identifying compounds modifying a cellular phenotype”. Together with 2cureX’s existing patent portfolio, the patent provides a broad protection of the company’s IndiTreat® technology in its European launch markets.

Significant events after the end of the period

• 2cureX receives CE-IVD marking of its product IndiTreat®. The CE-IVD labelling entitles 2cureX the right to sell IndiTreat® tests in Europe. The CE-IVD labelling places 2cureX in a unique position to successfully launch IndiTreat® on the European market as planned in 2020.

• 2cureX along with its clinical partner Vejle Hospital receives approval to launch a clinical trial in metastatic pancreatic cancer. IndiTreat® is thus being clinically validated in three major cancer diseases (colorectal, ovarian and pancreatic cancers).

Other events during the third quarter 2018

• 2cureX is invited to present at LSX (Life Science Executives, Leadership and Investment) Congress in Stockholm on August 29-30, 2018.

• 2cureX presents its business at e.g. Sedermeradagen Göteborg, EIC Innovator’s Summit, Berlin.

• 2cureX GmbH secures payment of a grant of EUR 810,000 through an approved on-site inspection at the company’s facilities.

• 2cureX announces that one of its clinical partners, Vejle Hospital presented a poster at the ESMO (European Society for Medical Oncology) congress in Munich 19-23 October 2018. Abstract of the poster can be found here. 

CEO Ole Thastrup comments

"We have come across a major obstacle on the road of becoming a commercial MedTech company by receiving CE-IVD labelling of IndiTreat® in October 2018. IndiTreat® is currently being validated clinically in three major cancer indications. The next step is to continue working with our strong clinical partners, more Key Opinion Leaders and potential customers to prepare the markets in the Nordic countries, Germany and the UK before launching IndiTreat®, which is planned in 2020."

For the full interim report (only Swedish), please see https://www.2curex.com/investors/reports/

Certified Adviser

Sedermera Fondkommission is the Certified Adviser of 2cureX.

For more information about 2cureX:

This is information that 2cureX AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication on the 23rd of November, 2018

About 2cureX

2cureX has developed a test called IndiTreat® (Individual Treatment Design), which is a patented and CE-IVD marked test for selecting the right drug for the right patient. IndiTreat® establishes thousands of 3D micro-tumors that are functionally similar to the patient’s tumor. From a large panel of approved cancer treatments IndiTreat® presents the best treatment for the individual patient. IndiTreat® is expected to become a standard tool in the treatment design for cancer patients.

IndiTreat® is currently being clinically validated in colorectal, ovarian and pancreatic cancer.

The company is listed at the Nasdaq First North stock exchange in Stockholm (symbol “2CUREX”). 

Tags: